OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology International is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	163
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	104
Platelets in acute liver failure: an innocent bystander or instigator?	80
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	79
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	65
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	59
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	56
Beyond left versus right: from puncture site selection to clinical strategy in TIPS	55
Precision medicine for G-CSF in ACLF: the biomarker gap	54
Metabolically healthy obese and MAFLD: does weight status alone matter?	50
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	48
Letter to the Editor: Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study	46
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	46
Comment on “Diabetes mellitus is linked to higher mortality in alcohol‑related acute‑on‑chronic liver failure”	45
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	44
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	44
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	44
Comment on “Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study”	43
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	43
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	42
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	41
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	41
Noninvasive risk stratification of liver nodule development in Fontan-associated liver disease using liver stiffness measurement	40
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	40
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	40

Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	40
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	40
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	39
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	38
Comment on “Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon”	38
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	37
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	36
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	35
Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation	35
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	34
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	34